FXR, Organovo and Eli Lilly

Eli Lilly pays $10m upfront for Organovo’s FXR agonist
Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ farnesoid X receptor (FXR) agonist programme, aimed at treating inflammatory bowel disease (IBD).
Eli Lilly buys Organovo's FXR program for $10M, sending biotech's stock skyrocketing 244%
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. | Eli Lilly has acquired Organovo’s lead asset,
M&A News: Eli Lilly (LLY) Expands IBD Pipeline with Organovo’s FXR Program
The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid X receptor (FXR) agonists,
Lil­ly pays $10M up­front for Organo­vo’s FXR ag­o­nist pro­gram
Eli Lilly is buying Organovo’s farnesoid X receptor (FXR) agonist program, which includes a drug in Phase 2 development for ulcerative colitis and metabolic dysfunction-associated steatohepatitis (MASH),
Organovo, Inc.: Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company
Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches
Organovo’s FXR program to be acquired by Eli Lilly
Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314.
Why Eli Lilly Stock Popped Today
Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...
Lilly plans to invest $27 billion in new US plants as Trump threatens pharmaceutical tariffs
Eli Lilly plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a ...
Why Organovo (ONVO) Stock Is Skyrocketing
Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR ...
MT Newswires on MSN1d
Eli Lilly Expands Zepbound Vial Dose Options, Cuts Weight-Loss Drug's Prices for Self-Pay Patients
Eli Lilly (LLY) on Tuesday launched higher doses of Zepbound, or tirzepatide, in single-dose vials and reduced the prices of two smaller doses of the weight-loss drug for self-pay patients. The ...
Investor ideas22h
Biotech Stock Organovo Holdings (Nasdaq: ONVO) Soars on Eli Lilly (NYSE: LLY) Deal
Organovo today announced that Eli Lilly and Company (NYSE:LLY) ("Lilly") will acquire Organovo's FXR program, including its ...
Yahoo Finance1d
Eli Lilly and Company (LLY)
today announced that Eli Lilly and Company (NYSE:LLY) (“Lilly”) will acquire Organovo’s FXR program, including its lead asset, FXR314. “This is a significant milestone for our efforts to ...
Eli Lilly Bets Big on Weight-Loss Pill With $550 Million Inventory Stockpile
(Reuters) - Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage ...